Stock Research for MRK

MRK

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

MRK Stock Chart & Research Data

The MRK chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MRK chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


MRK Due diligence Resources & Stock Charts

The MRK stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View MRK Detailed Price Forecast - CNN Money CNN View MRK Detailed Summary - Google Finance
Yahoo View MRK Detailed Summary - Yahoo! Finance Zacks View MRK Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View MRK Trends & Analysis - Trade-Ideas Barrons View MRK Major Holders - Barrons
NASDAQ View MRK Call Transcripts - NASDAQ Seeking View MRK Breaking News & Analysis - Seeking Alpha
Spotlight View MRK Annual Report - CompanySpotlight.com OTC Report View MRK OTC Short Report - OTCShortReport.com
TradeKing View MRK Fundamentals - TradeKing Charts View MRK SEC Filings - Bar Chart
WSJ View Historical Prices for MRK - The WSJ Morningstar View Performance/Total Return for MRK - Morningstar
MarketWatch View the Analyst Estimates for MRK - MarketWatch CNBC View the Earnings History for MRK - CNBC
StockMarketWatch View the MRK Earnings - StockMarketWatch MacroAxis View MRK Buy or Sell Recommendations - MacroAxis
Bullish View the MRK Bullish Patterns - American Bulls Short Pains View MRK Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View MRK Stock Mentions - StockTwits PennyStocks View MRK Stock Mentions - PennyStockTweets
Twitter View MRK Stock Mentions - Twitter Invest Hub View MRK Investment Forum News - Investor Hub
Yahoo View MRK Stock Mentions - Yahoo! Message Board Seeking Alpha View MRK Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for MRK - SECform4.com Insider Cow View Insider Transactions for MRK - Insider Cow
CNBC View MRK Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for MRK - OTC Markets
Yahoo View Insider Transactions for MRK - Yahoo! Finance NASDAQ View Institutional Holdings for MRK - NASDAQ


Stock Charts

FinViz View MRK Stock Insight & Charts - FinViz.com StockCharts View MRK Investment Charts - StockCharts.com
BarChart View MRK Stock Overview & Charts - BarChart Trading View View MRK User Generated Charts - Trading View




Latest Financial News for MRK


Merck (MRK) Q1 2024 Earnings Call Transcript
Posted on Thursday April 25, 2024

MRK earnings call for the period ending March 31, 2024.


Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook
Posted on Thursday April 25, 2024

On Thursday, U.S. drug maker Merck & Co Inc (NYSE:MRK) reported first-quarter sales of $15.8 billion, up 9% year-over-year, beating the consensus estimate of $15.2 billion. Excluding the impact of foreign exchange, sales increased 24%. Merck reported adjusted EPS of $2.07, up 48%Y/Y, beating the consensus of $1.88. Merck’s pharmaceutical unit booked $14.01 billion in revenue during the first quarter, up 10% Y/Y. Related: Merck’s $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease. Me


Merck (MRK) Q1 Earnings Top, Cancer Drug Keytruda Boosts Sales
Posted on Thursday April 25, 2024

Merck (MRK) beats first-quarter estimates for earnings and sales. The company raises its EPS range for 2024. Stock rises in pre-market.


Heard on the Street: Bristol-Myers Goes From Big Pharma to Little Pharma
Posted on Thursday April 25, 2024

Bristol-Myers Squibb’s market capitalization has dropped so much over the past year that it is now arguably no longer part of the big pharma club. After reporting disappointing earnings figures on Thursday, the company’s shares fell sharply, giving it a market capitalization of about $95 billion. The problem for Bristol-Myers is that its older blockbuster products, cancer drug Revlimid and blood thinner Eliquis, are expected to decline in the coming years and investors aren’t convinced that the company has enough growth drivers in the near term.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.